Alphamab Oncology Reports 2024 Interim Results and Business Highlights [Yahoo! Finance]
ArriVent BioPharma, Inc. (AVBP)
Company Research
Source: Yahoo! Finance
Financial Summary For the six months ended June 30, 2024 , we recorded total revenue of RMB 173.56 million , an increase of 27.18% compared with the first half of 2023. Meanwhile, product revenue amounted to RMB 90.64 million , a decrease of 22.54% compared with the same period of prior year. For the six months ended June 30, 2024 , our R&D expenditure amounted to RMB 194.53 million , basically unchanged as compared with the same period of prior year. For the six months ended June 30, 2024 , we recorded loss for the period of RMB 44.90 million . The loss for the period excluding exchange gain and loss was RMB 52.19 million , a decrease of 41.17% compared with the first half of 2023. We have a healthy financial position, with cash reserves of RMB 1,456.59 million as of June 30, 2024 Business Highlights Product Pipeline Distinguished by a globally competitive pipeline, the Company specializes in antibody-drug conjugation (ADC), single domain antibody, and multi-functional
Show less
Read more
Impact Snapshot
Event Time:
AVBP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVBP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVBP alerts
High impacting ArriVent BioPharma, Inc. news events
Weekly update
A roundup of the hottest topics
AVBP
News
- ArriVent BioPharma: Bringing A Novel Cancer Drug From China [Seeking Alpha]Seeking Alpha
- ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its price target raised by analysts at Citigroup Inc. from $30.00 to $36.00. They now have a "buy" rating on the stock.MarketBeat
- ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $39.00 price target on the stock, up previously from $35.00.MarketBeat
- ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $28.00 to $38.00. They now have a "buy" rating on the stock.MarketBeat
- ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its price target raised by analysts at HC Wainwright from $30.00 to $36.00. They now have a "buy" rating on the stock.MarketBeat
AVBP
Earnings
- 8/14/24 - In-Line
AVBP
Sec Filings
- 11/12/24 - Form SC
- 11/12/24 - Form SC
- 11/8/24 - Form SC
- AVBP's page on the SEC website